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Abstract 
The human body is made up of trillions of cells. Although all the human body cells contain the same DNA 
sequence inside their nuclei, each one carries out its own function. Normally, human cells grow and 
divide to form daughter cells as the body needs them. When cells grow old, or lose their ability to function 
properly, they die (in a very organized way called apoptosis or programmed cell death) and new cells 
take their role. Cancer is a disease that is caused by uncontrolled division of abnormal cells in some part 
of the body, breaking the natural process of growing. Old or damaged cells survive when they should die, 
and new (abnormal) cells form when they are not needed. Some types of cancer form solid tumors, 
which are masses of tissue. Others, such as leukemias, do not form solid tumors. It is widely believed 
that cancer is caused by the accumulation of detrimental variation in the genome over the course of a 
lifetime. Variations can take several forms. Single Nucleotide Polymorphism (SNP) is a mutation in a 
single base of the DNA. Indels describe insertions or deletions of bases in the genome. Copy Number 
Variation (CNV) represents multiplied and deleted segments in a genome. Most of the time, one type of 
mutation is not sufficient to induce cancer formation.  
In this study, we have investigated genomic datasets of a phase-1 clinical trial on triple-negative breast 
cancer and ovarian cancer patients. The goal is to identify genes that drive drug resistance. We have 
developed data analysis pipelines to obtain genomics variations (somatic mutations and copy number 
variations) from the Whole Exome Sequencing (WES) raw data of 35 triple-negative breast cancer 
(TNBC) and ovarian cancer patients. In addition, we have analyzed the gene expression levels and gene 
fusion from the RNA-Seq raw reads data for a subset of 16 patients. This study is an effort toward 
optimizing the integrative analysis of genomic datasets under certain limitations. The main limitation is 
the small number of samples in the clinical trial (as is the case in most clinical trials). Another challenge 
is to find an abstract way to analyze the raw sequencing data given its large size and heterogeneity. The 
novelty of our work comes in following a data science approach in answering such research questions. 
The unbiased and data-driven approach was successful in identifying genes that are most likely related 
to the drug resistance. Our results will guide clinicians toward having an in-depth study of the driver 
genes. 
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Chapter 1: Introduction 
The human body is made up of trillions of cells. Although all human body cells contain the same 
DNA sequence inside their nuclei, each one carries out its own function. Normally, human cells grow and 
divide to form daughter cells as the body needs them. When cells grow old, or lose their ability to function 
properly, they die (in a very organized way called apoptosis or programmed cell death) and new cells 
take their role. Cancer is a disease that is caused by uncontrolled division of abnormal cells in some part 
of the body, breaking the natural process of growing [1]. Old or damaged cells survive when they should 
die, and new (abnormal) cells form when they are not needed. Some types of cancer form solid tumors, 
which are masses of tissue. Others, such as leukemias, do not form solid tumors. 
The Cancer 
Cancer Research UK studies show that 8.2 million people died in 2012 worldwide because of 
cancer [2]. Worldwide, breast cancer accounts for nearly a quarter of all cancers in women and it is 
estimated that 1.7 million women are diagnosed with the disease annually. Although the incidence rates 
of invasive breast cancer have remained stable over the past several decades among women younger 
than 50, Figure 1 shows substantial changes in rates among women older than 50 years old. Moreover, 
Figure 2 shows the rate of metastatic breast cancer at initial diagnosis in the United States. There was 
no remarkable change in the rates despite the widespread use of mammography for early detection [3].  
 
Figure 1 -  U.S. incidence rates of invasive breast cancer among women <50 and ≥50, 1975-2012 
There are two categories of genes that are directly related to cancer. The first category is called 
oncogenes, which boost the activity of a cell to grow and divide abnormally. The second category is 
tumor-suppressor genes, which kill cells that goes through abnormal division path [1]. Cancer cells either 
over-express oncogenes, under-express tumor-suppressor genes or both. It has been revealed that 
cancer is caused by an accumulation of detrimental variation in the genome over the course of a lifetime. 
Variations can take several forms. Single Nucleotide Polymorphism (SNP) is a variation in a single base 
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of the DNA. Indels describe insertions or deletions of bases in a genome. Most of the time, a single 
mutation is not sufficient to induce cancer formation. Larger regions of mutations in the DNA lead to the 
dysfunction (over-expression or under-expression) of genes (oncogenes or tumor-suppressor genes) that 
ultimately cause cancer. 
 
Figure 2 - Female Breast Cancer Incidence Rates by Stage, US, 1975-2012 
 
Triple-Negative Breast Cancer (TNBC) and High Grade Serous Ovarian 
Cancer 
In this work, we focus our efforts on one type of breast cancer called Triple-Negative Breast 
Cancer (abbreviated TNBC) and its closely similar cancer, ovarian cancer [4]. TNBC refers to any type of 
breast cancer that does not express the genes for estrogen receptors (ER), progesterone receptors (PR) 
or HER2/neu receptors. HER2 is a type of oncogenes that is overexpressed in some types of breast 
cancer (ER negative, PR negative and HER2 negative). That’s why it is called triple negative. This 
classification leads to therapeutic implications because patients cannot benefit from endocrine therapy as 
it lacks ER and PR. In addition, they cannot benefit from Anti-HER2 agents since it is HER2 negative. 
This makes it more difficult to treat as most chemotherapies target one of the three receptors, so it 
requires a combination of therapies [5]. 
According to [6], TNBC accounts for 12-17% of all breast cancers. It is more prevalent in younger 
women (< 50 years) and African and Hispanic descent. There is a huge enrichment for tumors of the 
triple negative phenotype in the subset of patients with BRCA1 germline mutations. BRCA1 is considered 
as a tumor-suppressor gene responsible for the DNA repair, and a mutation in it causes immature 
daughter cells at cell replication. The same study showed that 80%-85% of BRCA1 breast cancers are 
triple negative and 10%-14% of TNBCs harbor BRCA1 mutations. TNBCs span from low grade tumors to 
high grade tumors. Similarly, the study in [7] revealed that 1.5% of women will be diagnosed with ovarian 
cancer. A woman with a mutation in the BRCA1 gene has a 40–60% lifetime risk of developing ovarian 
cancer [8]. For BRCA2 the lifetime risk is lower at 10–30%. However, it is still around a 10-fold higher risk 
than for the general population. 
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The huge heterogeneity remains a challenge when it comes to the histological features of TNBCs 
and ovarian cancers. First generation prognostic signatures, such as molecular classification, 
invasiveness gene signatures or tumor size, are of no use for triple negative disease [9]. That is because 
these first-generation prognostic signatures are nothing but feature counters. They identify tumors as of 
prognosis on the basis of high-expression levels of proliferation-related genes. Given that 97% of TNBC 
and 80% of ovarian cancers have high-expression levels of proliferation-related genes [10,11], they offer 
no discriminatory power.  
The Datasets 
We have sequencing data from a Phase I clinical trial study of the Oral PI3kinase-inhibitor (NVP-
BKM120) in combination with the Oral PARP-inhibitor (Olaparib) in patients with recurrent Triple 
Negative Breast Cancer or High Grade Serous Ovarian Cancer. Whole exome sequencing (WES) data 
of 35 patients from this study are available. There were a number of long-term responders to the regimen 
(> 6 months), raising the question as to what the genomic profile of the tumors that did respond was. 
RNAseq data of 8 responders and 8 non-responders of these 35 patients are also available. In summary, 
we have the following datasets: 
 DNA sequencing data. 
o WES of 35 tumors and their match normal samples 
 RNA sequencing data. 
o RNA-Seq of 16 tumors (8 responders and 8 non-responders) and 5 normal control 
 Clinical data 
o Drug response of sensitive and resistant groups. 
Source: Dr. Gerburg Wulf from BIDMC and Harvard Medical School provided WES and samples for 
RNA-Seq. RNA-Seq data have been generated by the CGI at UConn. All datasets are stored on UConn 
BBC HPC cluster [12]. 
Related Work 
To understand the mechanism of cancer, biomedical researchers are interested in identifying genomic 
aberrations that promote cancer development, known as drivers. They are also interested in profiling 
gene expression data to understand disease pathogenesis. It is hypothesized that driver genes involved 
in resistance likely have aberrant copy numbers and/or mutations and that the expression patterns of 
these genes match the mutation and copy number patterns [13]. The genomic aberrations, incorporated 
with gene expression profiles in disease progression, has motivated several studies. Huang N. et. al. 
have shared lessons extracted from over ten years of performing integrative analysis on cancer data [14]. 
Several methods have been used to integrate gene expression and CNV data. In general, these 
methods are based on three main approaches: 1-regression, 2-correlatin, and 3-module network. Linear 
approaches, such as regression analysis or correlation analysis, do not work properly for heterogeneous 
data that their within-group variations are extremely high, such as ovarian cancer data. Further, in 
general, the relationship between gene expression and structural variations is not linear. 
Kristensen V. et. al. surveyed the existing computational methodologies that are being used to assess 
cancer genomic data in [15]. In addition to the many tools surveyed, the review has assured that a more 
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fundamental understanding of the biological dynamics of cancer will enable us to better identify risk 
factors and refine cancer diagnosis. We can also predict therapeutic effects and prognosis, and identify 
new targets for therapy. The integrative analysis of genomic datasets introduced a paradigm shift from 
large randomized clinical trials towards treatment modalities that are tailored for stratified patient groups, 
down to N-of-1 trials, in which data from a single patient represents an entire trial. 
It has been shown that the module network analysis, which is a non-linear approach, performs well in 
identifying driver genes in cancer [16]. In [17], Nabavi S. has employed the module network analysis 
upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. The module 
network analysis is a form of Bayesian network analysis. However, similarly behaving variables (genes) 
can be grouped into modules (a group of genes) and that the network can learn the same parents and 
parameters for each module, instead of each variable, as in a Bayesian network. The main motivation for 
using module network analysis instead of regular Bayesian network analysis is that biological systems, 
similar to all complex systems, have too many variables but not enough data to robustly learn networks. 
In biological systems, we have thousands of genes but few samples. In addition, large networks are 
difficult to interpret, especially in biological systems. Moreover, it is assumed that genes that are co-
expressed are likely regulated in similar ways and might have the same drive. The study performed using 
module network analysis yielded a short list of aberrant genes that control the expression of their co-
regulated genes. Although the method introduced was successful, we could not utilize it in our study 
since the number of samples we have is very small. In order to identify candidate biomarkers, we had to 
employ techniques that perform better in our situation. 
Jennings E. et. al. performed an integrated analysis of heterogeneous genomic data using a hierarchical 
Bayesian analysis framework [18]. The framework incorporated the biological relationships among the 
different types of data to identify genes whose expression is related to clinical outcomes in cancer. This 
integrated approach lead to increased statistical power in finding these predictive genes, and further 
provided mechanistic information about the manner in which the gene affects the outcome. The study 
found 12 positive prognostic markers associated with nine genes and 13 negative prognostic markers 
associated with nine genes. 
In [19], Wang W. et. al. proposed and implemented an integrative Bayesian analysis of genomics data 
(iBAG) framework for identifying important genes/biomarkers that are associated with clinical outcome. 
This framework also used the hierarchical modeling approach to combine the heterogeneous data 
obtained from multiple platforms into one model. The performance of our methods using several 
synthetic and real examples showed that the integrative methods have a higher power to detect disease-
related genes than non-integrative methods. The methods were applied on the Cancer Genome Atlas 
glioblastoma dataset. The iBAG model integrated gene expression and methylation data to study their 
associations with patient survival. It discovered multiple methylation-regulated genes that are related to 
patient survival, most of which have important biological functions in other diseases but have not been 
previously studied in glioblastoma. 
Although the aforementioned studies slightly differ in their approaches and implementation, they share a 
common integrative analysis characteristic. In our study, we present a data science approach toward 
achieving the same goal of identifying candidate biomarkers for clinical outcomes.  
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Chapter 2: Genomic Features  
In this chapter, we cover important terminologies that we will use frequently in the subsequent 
chapters. We first start with basic definitions. Then, we discuss genomic features that will be the focus of 
our data analysis work. 
Basic Definitions 
The Body Cell 
A cell is the smallest unit of a living organism. It is made up of many even smaller parts, each with its 
own function. Human cells vary in size, but all are small and cannot by seen by the naked eye. Figure 3 
shows a breakdown of the human cell. The membrane holds the contents together. It also has receptors 
that bind to the signal molecules and communicate its presence inward into the cell. The receptors also 
react to substances produced in the body and to drugs taken into the body, selectively allowing these 
substances or drugs to trigger the cell functions. Reactions that take place at the receptors often alter or 
control a cell's functions. Within the cell membrane are two major components [20]: 
 The cytoplasm: contains structures that consume and transform energy and perform the cell's 
functions. 
 The nucleus: contains the cell's genetic material (DNA) and the structures that control cell division 
and reproduction. 
 
Figure 3 - Human Cell.  Credit: edited from RuguSavay.com 
The DNA 
The DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms. 
Every cell in a person’s body has the same DNA. It is located in the cell nucleus where it is divided into 
chromosomes. In humans, the DNA is divided into 23 pairs of chromosomes. The information in DNA is 
stored as a code made up of four chemical bases: adenine (A), cytosine (C), guanine (G), and thymine 
(T). Human DNA consists of about 3 billion of these bases. The order, or sequence, of these bases 
determines the information available for building and maintaining an organism, similar to the way in 
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which letters of the alphabet appear in a certain order to form words and sentences. As shown in Figure 
4, the DNA is a double helix formed by base pairs attached to a sugar-phosphate backbone [21].  
 
Figure 4 - DNA Structure. Credit: U.S National Library of Medicine 
Genes 
A gene is a region (or a set of non-overlapping regions) of the DNA that encodes for part of the cell 
functions. Each chromosome contains many genes. Genes act as instructions to make molecules called 
proteins. In humans, genes vary in size from a few hundred DNA bases to more than 2 million bases. 
Each gene consists of coding regions (exons) and non-coding regions (introns). The Human Genome 
Project has estimated that humans 
have between 20,000 and 25,000 
genes [22]. Every person has two 
copies of each gene, one inherited 
from each parent. Most genes are 
the same in all people, but a small 
number of genes (less than 1 
percent of the total) are slightly 
different between people. These 
differences contribute to each 
person’s unique physical features. 
Gene Expression 
The DNA nucleotides remain 
Figure 5 - Genes. Credit: U.S. National Library of Medicine 
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inside the cell’s nucleus. Some of them (genes) get copied to the cytoplasm in a process called gene 
expression. The ultimate product of gene expression are functional proteins, which can go on to perform 
essential functions as enzymes, hormones and receptors.  
Gene expression starts with the transcription process, which copies gene regions from inside the nucleus 
to the outside. Transcription starts from a promoter region and ends at a stop codon site. It results in a 
pre-messenger RNA (ribonucleic acid). The RNA is represented the same as DNA with letters: A, C, G 
and U (uracil, instead of T). The next step involves removing introns from the copied regions in a process 
known as splicing. It results in a mature mRNA. After that, the mature mRNA is translated into functional 
proteins. 
 
Figure 6 - Gene Expression. Credit: National Institute of Health 
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Proteins  
Proteins are the ultimate product of the gene expression process. They do most of the work in cells and 
are required for the structure, function, and regulation of the body’s tissues and organs. Proteins are 
made up of hundreds or thousands of smaller units called amino acids, which are attached to one 
another in long chains. There are 20 different types of amino acids that can be combined to make a 
protein. The sequence of amino acids determines each protein’s unique 3-dimensional structure and its 
specific function. Table 1 shows the genetic code: rules by which information encoded by genetic 
material (DNA and RNA) is translated into amino acids (identified from 3-mer sequences) that combined 
form a protein. 
Table 1 – Genetic Code 
 
 
Gene Fusion 
Due to abnormal cellular activities, two 
genes might fuse together at the 
transcription process forming a new gene 
as shown in Figure 7. This results a 
unique protein product at the end that 
might lead the cell to function improperly. 
  
Figure 7 - Gene Fusion. Credit: EMC Galaxy Training 
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Mutations 
Single Nucleotide Polymorphism (SNP) 
SNPs are variations in a single base pair in a DNA sequence as shown in Figure 8(a). 
Indel 
Indels are the insertion or the deletion of bases in the DNA of an organism as shown in Figure 8(b). 
 
Synonymous vs. Non-synonymous Variations  
In fact, not all mutations in the DNA are harmful and cause abnormal activity in the cell. Mutations can 
occur in non-coding regions which are not transcribed. Also, as we saw in the protein table previously, 
some sequences result in the same protein. Therefore, some variations are synonymous and result in 
the same ultimate protein sequence. In our study, we are interested only in non-synonymous variations. 
Figure 9shows a classification of variations. 
Variations
Non-coding 
region
Coding 
region
Synonymous
Non-
Synonymous
Missense
Nonsense
Figure 8 - Structural Variations. (a) SNP. Credit: International Society of Genetic Genealogy  
(b) Indels. Credit: Hackbright Academy. (c) CNVs. Credit: MindSpec.org 
Figure 9 – Types of variations 
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Non-synonymous variations of the type Missense results in a change in the protein as in the following 
example. 
DNA:  5' - AAC AGC CTG CGT ACG GCT CTC - 3' 
mRNA: 5' - AAC AGC CUG CGU ACG GCU CUC - 3' 
Protein:   Asn Ser Leu Arg Thr Ala Leu 
 A mutation:  
DNA:  5' - AAC AGC CTG CTT ACG GCT CTC - 3' 
mRNA: 5' - AAC AGC CUG CUU ACG GCU CUC - 3' 
Protein:   Asn Ser Leu Leu Thr Ala Leu 
Non-synonymous variations of type Nonsense causes the transcription to in an earlier position than the 
mature stop position. The following is an example.  
DNA:  5' - ATG ACT CAC CGA GCG CGA AGC TGA - 3' 
mRNA: 5' - AUG ACU CAC CGA GCG CGA AGC UGA - 3' 
Protein:   Met Thr His Arg Ala Arg Ser Stop 
 A mutation:  
DNA:  5' - ATG ACT CAC TGA GCG CGA AGC TGA - 3' 
mRNA: 5' - AUG ACU CAC UGA GCG CGA AGC UGA - 3' 
Protein:   Met Thr His Stop 
Structural Variations 
Some diseases, such as cancer, are caused by structural variations in the DNA [1]. Structural variations 
describe changes in the DNA sequence that might lead to a change in the proteins resulting from the 
gene expression process. We present the type of variations that we focused on during our study. 
Copy Number Variation (CNV) 
CNVs are a phenomenon in which parts of the genes are repeated or deleted. The number of 
repetition/deletion in the DNA varies between individuals in the human population. Figure 8(c) shows an 
example of a deletion on the left and an example of a duplication on the right. 
Genetics of Cancer 
Cancer is a genetic disease in most cases. It is caused by the abnormal cell division. Cells divide and 
grow in the presence of signals that normally inhibit abnormal cell growth [1]. As these cells grow, they 
develop new characteristics, including changes in DNA structure. Such changes allow the cancer cells to 
spread and invade other tissues, carrying with them their undesired characteristics. The abnormalities in 
cancer cells usually result from mutations in protein-encoding genes that regulate cell division. Over time 
more genes become mutated. This is mostly because the genes that make the proteins that normally 
repair DNA damage are themselves not functioning normally because they are also mutated. 
Consequently, mutations begin to increase in the cell, causing further abnormalities in that cell and the 
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daughter cells [1]. In cancer, somatic evolution is the accumulation of mutations in the cells of a body 
during a lifetime, and the effects of those mutations on the fitness of those cells. Somatic mutations can 
occur in any of the cells of the body except the germ cells (sperm and egg) and therefore are not passed 
on to children. These alterations can (but do not always) cause cancer or other diseases.  
Recall from chapter 1 that our clinical trial investigates the drug response of a the Oral PI3kinase-
inhibitor (NVP-BKM120) in combination with the Oral PARP-inhibitor (Olaparib) in patients with recurrent 
TNBC and ovarian cancer. In the next chapter, we discuss the data analysis pipelines we have 
developed for the whole exome sequencing (WES) and RNA Sequencing.  
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Chapter 3: Developing Pipelines for Analyzing High-throughput Data 
In this chapter, we present the development stages of our data analysis pipeline. Recall that we are 
given whole exome sequencing data for 35 patients and RNA sequencing data for a subset of 16 
patients. The next sections illustrate the pipelines in details. 
Whole Exome Sequencing 
Whole exome sequencing is a technique used for sequencing all the exonic regions of a genome. It 
starts by capturing only the regions of the DNA that encodes for proteins (i.e. exons). After that, 
instruments such as Illumina HiSeq are used to generate raw data files representing the DNA fragments 
(also known as short reads) [23]. Figure 10 shows the sequencing stages. For each patient, we obtained 
a sample from a normal tissue and another sample from the tumor tissue, which is the breast in our study. 
Then, using DNA templates in a flow cell, exons are extracted from the DNA. After that, a high-
throughput sequencer is used to read and interpret the short fragments into representations of the base 
pairs: A, C, G and T. 
 
Figure 10 - Whole Exome Sequencing. Credit: Canadian Bioinformatics Workshops 
Our study starts from the data analysis pipeline. We are given raw sequencing reads. Figure 11 shows 
the steps we have done in the analysis, followed by a detailed illustration of each step. The first two 
phases are considered as input to the pipeline. They have been performed under the supervision of Dr. 
Gerburg Wulf from BIDMC and Harvard Medical School. 
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Figure 11 – Whole Exome Sequencing (WES) pipeline 
Raw Reads 
Data from sequencing comes in raw text files in FASTQ format [24]. A FASTQ file normally uses four 
lines per sequence. Line 1 begins with a '@' character and is followed by a sequence identifier and an 
optional description. Line 2 is the raw sequence letters, which came in lengths of 100 base pairs in our 
study. Line 3 begins with a '+' character and is optionally followed by the same sequence identifier (and 
any description) again. Line 4 encodes the quality values for the sequence in Line 2, and must contain 
the same number of symbols as letters in the sequence. For example, A FASTQ file containing a single 
sequence looks like this: 
@SEQ_ID 
GATTTGGGGTTCAAAGCAGTATCGATCAAATAGTAAATCCATTTGTTCAACTCACAGTTT 
+ 
!''*((((***+))%%%++)(%%%%).1***-+*''))**55CCF>>>>>>CCCCCCC65 
The quality values are encoded using Phred quality scores. Phred quality scores are assigned to each 
nucleotide base call in automated sequencer traces. They have become widely accepted to characterize 
the quality of DNA sequences [24]. The quality scores become very important in the next step of the 
quality check. 
For each patient, we have received two sets of FASTQ files: files for normal tissue and files for the tumor 
tissue. The total size of all FASTQ files for all 35 patients is ~700 GB in a gzip compressed format. For 
the next pipeline phases, Linux scripts are provided for each task on the project’s GitHub repository [25]. 
Quality Check 
The current sequencing technologies produce errors in the read files. That’s why the quality score line is 
included in the FASTQ file for each read. In order to guarantee reliable results by the end of the analysis, 
we checked the quality of all FASTQ files using FASTQC v0.11.2 [26]. The summary reports showed no 
potential errors or warnings. Figure 12 shows an example of the report generated by the tool for one of 
the patients. Complete quality reports for all patients can be found on the project’s GitHub repository 
under variation-analysis folder. 
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Figure 12 - Per base sequence quality for one of the samples 
Alignment to the human genome 
Since the short reads are not in a 
specific order in the file, the next 
step in the pipeline is to map them to 
the human genome. Figure 13 
visualizes the reference genome in 
the top track and the short read 
mapping below it. The blue lines 
connect the pair-end reads. Red 
bars are the short reads. For the 
alignment, we have used the 
Burrows-Wheeler Aligner tool 
v0.7.12-r1039 [27] and mapped the 
reads to the human genome 
reference (Hg19) downloaded from 
UCSC genome browser [28]. 
 
 
Figure 13 - Short read alignment to the human genome. Credit: Wikipedia 
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Aligning each patient’s samples separately, we obtain two alignment files: one for normal and one for 
tumor. The alignment files are in SAM format (Sequence Alignment/Map) [29]. It is a TAB-delimited text 
format consisting of a header section, which is optional, and an alignment section. If present, the header 
must be prior to the alignments. Header lines start with ‘@’, while alignment lines do not. Each alignment 
line has 11 mandatory fields for essential alignment information such as mapping position, and variable 
number of optional fields for flexible or aligner specific information. The total size of all SAM files for all 
35 patients is ~3.5 TB. 
Preprocessing 
Before starting to analyze the alignment files for variation analysis, it is of great benefit to pre-process the 
data for future operations to take less time. Preprocessing includes sorting and indexing the aligned 
reads and converting the results to fixed binary files for faster analysis. For this task, we have used 
Picard v2.3.0 included in the GATK framework [30] following the best practices described in [31] and [32]. 
This reduced the size of our files to ~2.6 TB of processed alignment files along with indices. 
Somatic Variation Analysis 
In this step of the pipeline, we have analyzed the processed files in order to identify somatic variations. 
To achieve this, we perform a per-patient analysis comparing the patient’s normal file with the tumor file. 
SNPs as well as Indels. In this analysis, variations are identified for each patient with relative to her 
normal sample (not with the reference human genome). For this phase, we have used VarScan2 v2.4.2 
[33] with some intermediate steps done using SAMtools v1.2 and htslib v1.2.1 [29]. 
This phase results in the variations for each patient separately in VCF format (Variant Call Format) [34]. 
The VCF format stores sequence variations. For example: 
## header line 1 
## header line 2 
## rest of header lines 
#CHROM  POS  ID  REF  ALT  QUAL  FILTER  INFO  FORMAT  Sample1  Sample2 
2       4370 rs9 G    A    29    .       NS=.. DP:HQ.. 0|0:48.. 0|0:46.. 
: 
: 
Table 2 gives a brief description for each column: 
Table 2 - Columns of the VCF file 
 Name Brief Description 
1 CHROM The name of the sequence (a chromosome) on which the variation is being called. 
2 POS The 1-based position of the variation on the given sequence. 
3 ID The identifier of the variation 
4 REF The reference base (or bases in the case of an Indel at the given position on the given 
reference sequence. 
5 ALT The list of alternative alleles at this position. 
6 QUAL A quality score associated with the inference of the given alleles. 
7 FILTER A flag indicating which of a given set of filters the variation has passed. 
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8 INFO An extensible list of key-value pairs (fields) describing the variation. 
9 FORMAT An (optional) extensible list of fields for describing the samples. 
10 Samples (optional) For each sample, values are given for the fields listed in FORMAT. 
 
Since we do not expect a large number of variations in each patient, VCF files are small files in the order 
of a few Megabytes. They serve one of our core analysis assets in the next chapter. 
Copy Number Variation Analysis 
As with the somatic variation analysis, we have analyzed the processed files in order to identify CNVs. 
This is also a per-patient analysis where we used VarScan2 as well. This step results in the CNVs for 
each patient separately in a TAB-delimited format. It stores information about the copy numbers. 
For example: 
chrom  start  stop  num_positions  normal_depth  tumor_depth  log2_ratio  gc_content 
chr1   1489   1588  100            24.1          10.6         -1.182      41.0 
: 
: 
Table 3 gives a brief description for each column. 
Table 3 - Columns of the CNV output file 
 Name Brief Description 
1 chrom Chromosome or reference name. 
2 start Start position of a contiguous copy number region (1-based). 
3 stop Stop position of a contiguous copy number region (1-based). 
4 num_positions Length of the region. 
5 normal_depth Average sequence depth in the normal. 
6 tumor_depth Average sequence depth in the tumor. 
7 log2_ratio Log-base-2 ratio of the tumor/normal depth ratio. 
8 gc_content Proportion of GC bases in the region, between 0 and 100. 
 
After that, we have processed the copy number data as following: 
 Filter the copy number calls by minimum coverage and/or region size. 
 Adjust raw copy number (log2) values for GC content. 
 Classify each region as amplification (gain), deletion (loss), or neutral based on your preferred 
log2 thresholds. 
 Re-center raw copy number data if neutral segments are not on the log2=0 axis. 
VarScan2 provides an implementation for this filtering/adjustment. Therefore, we have integrated it in our 
pipeline. The file maps the repeated/deleted segments of the DNA to the corresponding chromosomes 
and marks the start/end positions along with the log ratio of the copy number value. The raw output from 
that phase of the pipeline is then smoothed and segmented using DNAcopy package in R [35]. The 
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package analyses the data to detect larger regions with abnormal copy numbers. Another filtering that 
we have applied is removing the copy number regions that have a log ratio in the range of [−0.5, 0.5]. 
This ensures that further analysis relies only on significant copy number values that denote a true 
duplication or deletion. After that, we map the CNV regions to the list of known genes in RefSeq 
database [36] with the goal of identifying the CNV genes.  
Gene Annotation 
The last step in this pipeline is to annotate the discovered mutations (SNPs and Indels) with regard to 
genes and proteins. The idea is to define what aberrations fall into what exons of the known genes and 
can change which protein. The obtain a comprehensive list of known genes along with their start/end 
positions, we have used RefSeq database [36] which we obtained from UCSC genome browser. We 
have used ANNOVAR v2016-02-01 to perform the annotation step [37]. 
By the end of the first data analysis pipeline, we have obtained the following for each patient: 
1. A list of genes that have somatic mutations. 
2. A list of genes that have CNVs. 
 
RNA Sequencing 
Similar to WES, RNA-Seq aims at obtaining short reads for the genomic features. However, instead of 
capturing base pairs from the DNA samples, it operates on the RNA samples and quantifies presence of 
mRNA at a given moment in time [38]. RNA-Seq facilitates the study of changes at the gene expression 
in a given sample. Therefore, it is a tissue- and time-specific. Similar to the sequencing stages illustrated 
in Figure 10, RNA-Seq follows the same stages except that we isolate RNAs instead of the exons. We 
also study the gene expression only in the tumor tissue and compare it with the gene expression from 
the same tissue in normal population. 
Figure 14 of the downstream data analysis is similar to the analysis we did in the WES pipeline. However, 
there is a number of differences due to the special nature of the RNA sequencing process. We explain 
them in the next subsections.  
 
Figure 14 – RNA-Seq pipeline 
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Raw Reads and Quality Check 
Similar to WES, data comes in raw text files in FASTQ format. For each patient, we have received a set 
of FASTQ files for sequenced tissue. Sequencing of 8 patients (out of 16) were carried out from the 
breast tissue. Sequencing for the other 8 patients were performed from the ovarian tissue. The reason 
for that is that breast and ovarian cancers share common features. In addition, we have sequencing data 
for 5 normal samples from the breast tissue of healthy women. The total size of all FASTQ files for all 21 
patients is ~105 GB in a gzip compressed format. For the next pipeline phases, Linux scripts are 
provided for each task on the project’s GitHub repository [25]. 
 
Figure 15 - Per base sequence quality for one RNA-Seq sample 
The quality check summary reports showed no potential errors or warnings. Figure 15 shows an example 
of the report generated by FASTQC for one of the RNA-Seq samples. Complete quality reports for all 
patients can be found on the project’s GitHub repository under gene-analysis folder. 
Alignment and Pre-processing 
The next step in the pipeline is to map the short reads to the human genome. There is a crucial 
difference from the WES reads alignment. Since RNA-Seq isolates RNAs instead of exons, generated 
reads come from different exons regions. In other words, one read might not be mapped as one fragment 
to the human genome; parts of the read may come from different exonic regions. Therefore, we have to 
use an aligner that is aware of the splices. Therefore, we have used the STAR Aligner tool v020201 [39] 
and mapped the reads to the human genome reference (Hg19) downloaded from UCSC genome 
browser [28]. Figure 16 visualizes the spliced read alignment in RNA-Seq data. 
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Figure 16 - Spliced read alignment to the human genome. Credit: edited from [40] 
We have obtained the alignment file for each sample. The alignment files are in SAM format and the total 
size of all SAM files for all 21 samples is ~300 GB. We have proceeded with the pre-processing of the 
alignment data to have a faster analysis in the subsequent pipeline steps. 
Gene Expression Analysis 
Gene expression is the most basic level at which the genotype gives rise to the phenotype. In other 
words, gene expression is affected by the genomic features at the DNA level and affects the observable 
results such as the drug response in our clinical trial. The goal of this phase is to quantify the expression 
levels of known genes in each of the given samples. To achieve this, we perform a per-sample analysis 
calculating the number of reads that lie in known gene regions. The more reads we find in a known gene, 
the more expression level this gene has. A number of normalization and statistical testing steps are 
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performed afterwards to remove biases. Fortunately, existing software packages carry out this task 
efficiently. We have used RSEM v1.2.31 [41] with Ensembl gene annotation database [42].  
This phase results in the gene expression level for each sample separately in TAB-delimited format. It 
stores information about the read counts for each gene. For example: 
 
gene_id  transcript_id(s)  length  effective_length  expected_count  TPM  FPKM 
ENSG003  ENST049,ENST0731  2201.90 2096.31           1803.00         9.67 20.07 
: 
: 
Table 4 gives a brief description for each column: 
Table 4 - Columns of the gene expression output file 
 Name Brief Description 
1 gene_id The Ensembl gene ID of a known gene. 
2 transcript_id(s) The Ensembl transcript ID (or IDs) corresponding to the gene ID above. 
3 length The transcript's sequence length. 
4 effective_length It counts only the positions that can generate a valid fragment. 
5 expected_count1 The sum of the posterior probability of each read comes from this transcript over 
all reads. 
6 TPM It stands for Transcripts Per Million. It is a relative measure of transcript 
abundance. The sum of all transcripts' TPM is 1 million. 
7 FPKM2 It stands for Fragments Per Kilobase of transcript per Million mapped reads. It is 
another relative measure of transcript abundance. 
 
1 Each read aligning to a transcript has a probability of being generated from background noise, that’s 
why it takes into account the probabilities. RSEM may filter some aligned low quality reads, the sum of 
expected counts for all transcript are generally less than the total number of reads aligned. 
2 FPKM is calculated as following: 
Let 𝑙 ̅be the mean transcript length in a sample, 𝑙 ̅ =  ∑ 𝑇𝑃𝑀𝑖
𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒_𝑙𝑒𝑛𝑔𝑡ℎ𝑖
106𝑖
, where 𝑖 is the transcript 
number. We get, 𝐹𝑃𝐾𝑀𝑖 = 
103
𝑙 ̅
 × 𝑇𝑃𝑀𝑖 
Gene Fusion Analysis 
Recall from the previous chapter that two genes (or part) might fuse together forming a new gene that 
ends with an unknown transcript. Therefore, the gene expression analysis cannot capture the gene 
fusion phenomenon, since the new transcript maps to two different (and maybe distant) genes. This is 
different from spliced alignment that takes into account different exons of a single gene. Fusion occurs 
mostly due to genomic aberrations. 
In this step of the pipeline, we have used Fusion Catcher v0.99.6a beta [43]. It searches for novel as well 
as known somatic fusion genes, translocations, and chimeras in RNA-Seq data from disease samples. 
translocation is a chromosome abnormality caused by rearrangement of parts between chromosomes. 
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The tool shows very good detection rate for finding candidate somatic fusion genes. It stores information 
about the candidate fused transcripts for each sample in a TAB-delimited file. Some of the columns are 
shown below: 
gene_1  gene_2  fusion_description  spanning_pairs  fusion_sequence fused_transcript 
ATAD2   NPM1    cancer_tissues      5               ..CTGA*GTCA..   ..TGAAG*ATGATG.. 
: 
: 
Table 5 shows some of the columns of the Fusion Catcher output. The original full list of columns can be 
found on the tool documentation files.  
Table 5 - Columns of the gene fusion output file 
 Name Brief Description 
1 gene_1 Gene symbol of the 5' end fusion partner. 
2 gene_2 Gene symbol of the 3' end fusion partner. 
3 fusion_description Type of the fused gene referring to known database if it is a known fusion or 
uniquely identified. 
4 spanning_pairs Count of pair-end reads supporting the fusion. 
5 fusion_sequence The inferred fusion junction (the asterisk sign marks the junction point). 
6 fused_transcript All possible known fused transcripts 
 
Summary 
In this chapter, we have covered the development stages of the data analysis pipelines. We have 
developed and executed the necessary stages of obtaining genomic variation data as well as the gene 
profiling data for the patients covered in our study. We have utilized a number of existing software tools 
in different stages of the pipeline with the goal of optimizing the pipeline execution and obtaining reliable 
results. 
In the next chapter, we proceed to the next step of the study in which we mine the output files from the 
developed pipelines to perform further analysis. 
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Chapter 4: Data Analysis 
So far, we have been able to transfer the raw sequencing data into meaningful per-patient genomic 
features. We have obtained the somatic variation (SNP and Indel), CNV, gene expression and gene 
fusion data. In addition, we know that patients under study are treated with Oral PI3kinase-inhibitor 
(NVP-BKM120) in combination with the Oral PARP-inhibitor (Olaparib). Half of them responded to the 
treatment and the other half did not respond. We consider the availability of WES and RNA-Seq data for 
those patients. In this part of our study, we analyze the patients’ data obtained from the pipelines 
illustrated in the previous chapter. The goal is to try answering the following question: 
Can we identify candidate genomic biomarkers that drive drug resistance? 
In other words, can we find aberrations in some genes of the non-responding patients that do not exist in 
the responders? The nature of this question implies the following challenges: 
 Data Heterogeneity: as we have seen from the previous chapter, the datasets have different 
formats and represent different biological meanings. 
 Feature selection: with the large number of features (genes) under study, we should use 
appropriate feature selection or dimensionality reduction methods to identify only the features that 
are biologically meaningful. 
 Small sample size: the number of samples is relatively small. This imposes a challenge in 
applying machine learning and statistical methods. 
Approach 
The integrative analysis of genomic datasets comes in different flavors. We discuss the different 
approaches in the next chapter. In our study, we have followed a data science approach. The motivation 
is to extract knowledge from data. We aim at applying a wide range of techniques that guide our search 
for a smaller feature list.  
The hypothesis we followed in shown in Figure 17. The hypothesis is that the drug response is most 
likely the result of the functional proteins produced by the tissue cells along with some other unknown 
factor 𝜃1. As we have shown in chapter 2, proteins are the ultimate results of gene expression. Therefore, 
they are affected by the transcribed mRNAs that represent genes. Fused genes also play a non-
negligible role since they might lead to producing new proteins. Besides, the unknown factor  𝜃2 affects 
the functional proteins. Gene expression and gene fusion are a result of the DNA features. Therefore, 
aberrations in the DNA are considered the root cause of the drug response, without neglecting the third 
unknown factor  𝜃3. 
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Figure 17 - Data Analysis Approach 
Why did we include the unknown factors 𝜃𝑠? In general, the living organisms have a very complex 
system of operation that cannot be modeled in a computation. Thus, being able to model many cellular 
processes such as the gene expression and aberrations does not mean that we have modeled all cellular 
processes. Without the loss of generality, Figure 17 captures all the data available in our study. In the 
next sections, we explain our data mining and analysis steps and drive conclusions afterwards. 
Data Crunching 
In the previous chapter, we have seen how heterogeneous the data resulted from the pipelines is. To 
perform any further analysis, we have to pre-process the data and construct meaningful data structures. 
Therefore, we have formulated four matrices; one for each of the genomic features. We present the 
process of obtaining them in the next subsections.  
Gene Expression Matrix 
The RNA-Seq data is tissue-specific. The data for the patients were sequenced from the breast for a 
number of patients and the ovarian from the rest of them. The belief is that breast cancer and ovarian 
cancer share many genotype features. Therefore, by mining the gene expression file for each patient, we 
have obtained two separate matrices for each type of RNA sequencing: 𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 for the breast samples 
and 𝑀1𝑜𝑣𝑎𝑟𝑖𝑎𝑛 for the ovarian samples. We construct the matrix as following: 
𝑀1 =  
[
 
 
 
 
 
 
𝑔1
𝑔2
𝑝1 𝑝2
⋯
𝑝𝑛
⋮ ⋱ ⋮
𝑔𝑘
𝑟
⋯ ]
 
 
 
 
 
 
Where 𝑔 stands for the gene, 𝑝 stands for the patient and 𝑟 stands for the drug response. The value at 
the 𝑟 row is 1 if the patient responded to the drug and 0 if she belongs to the non-responders group. The 
values in each cell of the matrix represents the gene expression value as either normalized read count or 
transcript per million (TPM). 
 
 24 
Normalized Read Count Matrix 
The value in each one of these cells represents the normalized read count of gene 𝑔𝑖 for patient 𝑝𝑗 for all 
𝑖 ∈ [1, 2, . . . , 𝑘] and 𝑗 ∈ [1, 2, . . . , 𝑛], where k is the number of genes and n is the number of samples.  
Transcript Per Million (TPM) Matrix 
The value in each one of these cells represents the TPM value of gene 𝑔𝑖  for patient 𝑝𝑗  for all 𝑖 ∈
[1, 2, . . . , 𝑘] and 𝑗 ∈ [1, 2, . . . , 𝑛]. The TPM is a metric used to normalize for sequencing depth and gene 
length. The software tool obtains it using the following operations: 
1. Divide the read counts by the length of each gene in kilobases. This gives us reads per kilobase 
(RPK). 
2. Count up all the RPK values in a sample and divide this number by 1,000,000. This is the “per 
million” scaling factor. 
3. Divide the RPK values by the “per million” scaling factor. This gives the TPM. 
Gene Fusion Matrix 
From the RNA-Seq data, we have obtained the genes that showed fused transcripts for each patient. By 
mining the gene fusion file for each patient, we construct the matrix 𝑀2 in the same way we constructed 
𝑀1 as following: 
𝑀2 =  
[
 
 
 
 
 
 
𝑔1
𝑔2
𝑝1 𝑝2
⋯
𝑝𝑛
⋮ ⋱ ⋮
𝑔𝑘
𝑟
⋯ ]
 
 
 
 
 
 
The value in each one of the cells = {
1   𝑖𝑓 𝑡ℎ𝑒 𝑔𝑒𝑛𝑒 𝑖𝑠 𝑓𝑢𝑠𝑒𝑑
0                       𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
    for each gene 𝑔𝑖 and patient 𝑝𝑗, where 𝑖 ∈
[1, 2, . . . , 𝑘] and 𝑗 ∈ [1, 2, . . . , 𝑛]. We can notice that this matrix is very sparse containing a very large 
number of zeros, since each patient has a very few number of fused genes (less than 10). 
Somatic Variation Matrix 
For each patient, we have obtained the annotated somatic variation file. The file maps mutations to the 
corresponding genes from the RefSeq database [36]. We are only interested in variations that are 
nonsynonymous. Therefore, we have filtered each patient’s file to opt out synonymous variations. Similar 
to 𝑀1 and 𝑀2, we construct the following matrix: 
𝑀3 =  
[
 
 
 
 
 
 
𝑔1
𝑔2
𝑝1 𝑝2
⋯
𝑝𝑛
⋮ ⋱ ⋮
𝑔𝑘
𝑟
⋯ ]
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The value in each one of these cells is 1 if there is a nonsynonymous variation in gene 𝑔𝑖 for patient 𝑝𝑗 
and 0 otherwise for all 𝑖 ∈ [1, 2, . . . , 𝑘] and 𝑗 ∈ [1, 2, . . . , 𝑛]. This matrix also has a high level of sparsity. 
CNV Matrix 
For each patient, we have obtained the annotated CNV file. Although the filtering done in the pipeline 
seems firm, it resulted into thousands of CNV genes per patient. Of course, further analysis would fail if 
we keep this number as it is for the reason that the number of features will be too large to have a 
significant contribution to the drug response. 
One further filtering step we have implemented is integrating the TPM value of a given gene for each 
patient with the CNV values. Figure 18 illustrates this filtering step. For each patient, we sample the 
values of genes TPM along the 𝑥 axis. We will then investigate only the genes in the first and last quartile. 
We include the gene in our analysis only 
if:  
 The gene lies in the first quartile 
and has a negative log ratio of the 
copy number, or 
 The gene lies in the last quartile 
and has a positive log ratio of the 
copy number. 
In a nutshell, this filtering keep only the 
genes that their CNV value is in the same 
direction of their transcripts expression 
value. The results is a reasonable number 
of CNV genes per patient that their copy numbers are aligned with their expression levels (in the order of 
100s). Similar to 𝑀1, 𝑀2 and 𝑀3, we contruct the matrix 𝑀4 as following: 
𝑀4 =  
[
 
 
 
 
 
 
𝑔1
𝑔2
𝑝1 𝑝2
⋯
𝑝𝑛
⋮ ⋱ ⋮
𝑔𝑘
𝑟
⋯ ]
 
 
 
 
 
 
The value in each one of these cells represents the log ratio of the copy number in gene 𝑔𝑖 for patient 𝑝𝑗 
for all 𝑖 ∈ [1, 2, . . . , 𝑘] and 𝑗 ∈ [1, 2, . . . , 𝑛]. We set the value equals to 0 if the gene is opted out by previous 
filtering. Figure 19 presents overall CNV profiles of responders and non-responder samples. This plot 
shows accumulative sum of the CNV values for the genomic segments across all the chromosomes as 
the Segment Gain Or Loss (SGOL) versus the chromosomes in both responders and non-responders 
groups. The SGOL tells us patterns of copy number gain (positive) as green signal and patterns of copy 
number loss (negative) as red signal. We can notice that most regions share close SGOL values 
between the two groups. That means that copy number variations cannot be the sole cause for the drug 
Figure 18 - Filtering CNV by TPM value 
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response. That’s why an integrative analysis is required for this study. Plots are generated using 
cghMCR package in R [44]. 
 
 
 
  
Figure 19 - CNV SGOL in responders and non-responders 
 27 
Feature Extraction 
Referring to Figure 17, our goal is to identify aberrant genes that affected the drug response as 
candidate biomarkers of drug resistance. The number of genes in each of the 𝑀1..4 matrices is 19,963. 
This is a relatively large number compared to the number of samples we have – 16. Therefore, the first 
step is to narrow down our search to a smaller number of genes. Our strategy is to go backward from the 
drug response (phenotype) to the aberrant genes (genotype). First, we have extracted genes that their 
expression levels differ significantly among the responder and non-responder samples. This computation 
is known as the differential expression analysis. We hypothesize that genes that have the same (or 
close) expression levels between the two groups are transcribed into proteins at the same level. Also, 
genes that are differentially expressed are transcribed into proteins at different levels. This should be a 
major contributing factor to the drug response. Second, we try to find a smaller set of genes that can 
classify the two groups. In the next two subsections, we will see that it is not possible to find such a 
reduced dimension features. In the following sections, we will illustrate how the analysis is steered from 
that point. 
Differential Expression Analysis 
The idea of differential expression (DE) analysis is to identify transcripts and genes that have significantly 
higher or lower level of abundance in the responder group compared to the non-responder group. To 
perform DE analysis, we have used EBSeq package [45]. Filtering out with a false discovery rate (FDR) 
of 0.05, we found that 𝟏𝟏𝟖𝟖  genes are differentially expressed between the responder and non-
responder groups in the breast sample. In the ovarian samples, we found that 𝟔𝟓𝟕  genes are 
differentially expressed. It is important to note that: 
 There are 𝟓𝟎 differentially expressed genes in common between both tissues (breast and 
ovarian).  |𝐷𝐸 𝑔𝑒𝑛𝑒𝑠𝑏𝑟𝑒𝑎𝑠𝑡|  ∩ |𝐷𝐸 𝑔𝑒𝑛𝑒𝑠𝑜𝑣𝑎𝑟𝑖𝑎𝑛| = 50 
 The total number of differentially expressed genes is 𝟏𝟐𝟏𝟔. 
|𝐷𝐸 𝑔𝑒𝑛𝑒𝑠𝑏𝑟𝑒𝑎𝑠𝑡|  ∪  |𝐷𝐸 𝑔𝑒𝑛𝑒𝑠𝑜𝑣𝑎𝑟𝑖𝑎𝑛| = 1216 
The result from the differential expression analysis reduced the size of 𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 to have only 1188 genes 
(dimensions), and the size of 𝑀1𝑜𝑣𝑟𝑎𝑖𝑎𝑛 to 657 genes (dimensions). However, this is still a large number 
for performing further regression or classification analysis. To further reduce the number of genes, we 
implemented a subsequent filtering step using the value of fold change. 
Filtering with Fold Change 
We removed the genes with low fold change (FC) from the two matrices (𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 and 𝑀1𝑜𝑣𝑎𝑟𝑖𝑎𝑛). Fold 
change is a measure describing how much a gene is over-expressed or down-regulated between the two 
groups. In order to decide the appropriate value of a threshold to use for filtering out low-concentration 
genes, we plotted the histograms of log2 of FC of all genes with FDR< 0.05 that is shown in Figure 20. 
We have noticed two small bumps around 1 and -1, which might be caused by an error. Therefore, we 
filtered out genes that lie in the range [-2, 2]. Since it is log2 ratio, this means that we are opting out 
genes with a fold change between 0.25 and 4 (0.25 < FC < 4). It turns out that there were 375 genes in 
this range in 𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 and 204 genes in this range in 𝑀1𝑜𝑣𝑎𝑟𝑖𝑎𝑛. Therefore, the remaining genes that we 
will focus on are 𝟖𝟏𝟑 genes in 𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 and 𝟒𝟓𝟑 in the ovarian matrix 𝑀1𝑜𝑣𝑎𝑟𝑖𝑎𝑛.  
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𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 = 
[
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⋯
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⋯ ]
 
 
 
 
 
 
 
 
Figure 21 shows the heat maps of the expression levels of the top 50 differentially expressed genes in 
both breast and ovarian samples. We can see significant over-expression in yellow in some genes of the 
non-responders group.   
 
  
Figure 20 - Histograms of gene expression fold change values 
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Figure 21 – Gene expression (log2 TPM). Left: breast samples. Right: ovarian samples 
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Dimensionality Reduction 
Given the differentially expressed genes 𝑀1𝑏𝑟𝑒𝑎𝑠𝑡 and 𝑀1𝑜𝑣𝑎𝑟𝑖𝑎𝑛, the question now becomes: can we 
classify the two groups and use them or some combination of them as a predictor of drug response? 
Having a naked-eye look at 𝑀2 and 𝑀3 after removing the non-differentially expressed genes, we did not 
see many aberrant genes among those DE genes as well. This motivated us to look for some 
combination of the genes to serve as predictors. 
The classical Principle Component Analysis (PCA) comes in handy for this purpose [46]. Figure 23 
shows a plot of principle component 1 versus 2 and principle component 1 versus 3 in the breast 
samples. Similarly, Error! Reference source not found. shows the same plots for the ovarian samples. 
Figure 23 - PCA in breast samples 
Figure 22 - PCA in ovarian samples 
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In principle component analysis, the first principle component is a linear combination of all the feature set 
(genes) that tries to capture the similarities between the data points. The second principle component 
should be a linear combination of all the feature set that tries to differentiate (separate) the data points 
above and below zero. Therefore, a successful PCA should show most data points in a small range over 
PC 1 and a clear separation between the data points over PC 2 or 3. However, the above figures show 
the exact opposite. Neither PC 1 could capture the similarities, nor PC 2 and 3 could separate between 
the responder and non-responder groups.  
This tells us that every trial to find a linear combination of the genes that can distinguish between the two 
groups will fail. The reason for that might be the very small number of data points, compared to the 
relatively large number of features. In addition, it tells us that separation between the responders and 
non-responders based on the gene expression does not help identify the aberrant genes accountable for 
the drug response. We can conclude that every patient has her own story of aberrations that led to 
certain genes to be expressed at a certain level. Therefore, we need to find a higher level of abstraction 
that can separate the two groups. Working on the small scale of DNA, RNA and gene expression is not 
the best way to perform such analysis with a small number of patients. 
Pathway Analysis 
Let’s zoom out from investigating at the genome level and look at a higher level of cell functions. We 
define molecular pathways to be a series of actions among molecules in a cell that leads to a certain cell 
function. Figure 24 shows an abstraction of a simple pathway scenario. Cell receptors bind to signal 
molecules triggering certain cell functions. For example, a gene regulatory network (GRN) is a collection 
of molecular regulators that interact with each other and with other substances in the cell to govern the 
gene expression levels of mRNA and proteins based on the signals received from the receptors. One 
pathway typically engages more than one gene and one gene is a member of several pathways. 
 
Figure 24 - Molecular pathways 
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The idea now is to investigate what pathways are involved in the aberrant genes for each patient 
separately, with the prospect that we can find common pathways among the non-responders that are not 
found in the responders. At that point, we can focus our analysis on one or two of the most significant 
pathways.  
 
Figure 25 - Per patient pathway analysis 
 
Figure 25 illustrates the pathway analysis that we performed. For each patient, we grouped together 
genes that have any kind of variations. We queried each matrix (𝑀2,𝑀3 𝑎𝑛𝑑 𝑀4)  after performing the 
filtration steps discussed earlier (not all 19,963 genes) and produced a shortlist of aberrant genes for 
each patient. Then, we have fetched their corresponding pathways. We have used KEGG pathways and 
employed the Gene Set Enrichment Analysis tool for connecting to the KEGG pathways database [47,48]. 
After that, we constructed the pathway matrix 𝑃 and drug response vector 𝑅 as following: 
𝑃 = 
[
 
 
 
 
 
 
𝑝1
𝑝2
𝑝𝑡ℎ𝑦1
  
  
𝑝𝑡ℎ𝑦2
  
  
⋯
𝑝𝑡ℎ𝑦𝑚−1 𝑝𝑡ℎ𝑦𝑚
 
 
 ⋮ ⋱               ⋮
𝑝𝑛       
     
  
    
⋯  
 ]
 
 
 
 
 
,     𝑅 =  [ : ] 
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The value in each one of the 𝑃 cells is equal to: 
𝑎𝑏𝑒𝑟𝑟𝑎𝑛𝑡 𝑔𝑒𝑛𝑒𝑠 𝑓𝑜𝑟 𝑝𝑖  ∩  𝑔𝑒𝑛𝑒 𝑠𝑒𝑡 𝑖𝑛 𝑝𝑡ℎ𝑦𝑗
𝑔𝑒𝑛𝑒 𝑠𝑒𝑡 𝑖𝑛 𝑝𝑡ℎ𝑦𝑗
 × 100.0 
for all 𝑖 ∈ [1, 2, . . . , 𝑛] and 𝑗 ∈ [1, 2, . . . , 𝑚], where m is the number of enriched pathways (m=133). We set 
the value equals to 0 if there are no aberrant genes in patient 𝑝𝑖 engaged in pathway 𝑝𝑡ℎ𝑦𝑗. The union of 
all pathways we got from the above queries was: 𝒎 = 𝟏𝟑𝟑. As an interpretation, the value in each cell of 
𝑃 tells us how much a given pathway is engaged in the aberrations for each patient. A smaller value 
means that there were few to no aberrations contributing to the drug response 𝑅 (0 𝑜𝑟 1). A larger value 
means that aberrations in that pathway contribute significantly to the drug response. The choice of these 
values will become justifiable in the next subsection. 
Regression 
Given the matrix 𝑃 , can we give a weight to each pathway that determines its effect on the drug 
response? It turns out that regression is a convenient solution for this problem [49]. We represent the 
matrix 𝑃 as the fixed input in the below illustration. Columns represent the pathways as features (𝑗 ∈
[1, 133]). Rows represent the patients’ data points. Values are as depicted in the previous subsection. 
The objective of regression algorithms is to estimate the drug response ?̂? using a coefficients vector 𝑊 
as shown in Figure 26.  
 
Figure 26 - Matrix setup for the regression analysis 
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Regression algorithms try to choose values for the 𝑊 vector that minimize the following: 
min
𝑊
 ‖𝑃𝑊 − 𝑅‖2
2
 
Figure 27 shows an example of a curve (blue) resulted from running regression on a sample of data 
points that have only one feature 𝑝0 . However, we have 133 features in our matrix 𝑃  and only 16 
samples (data point). The choice of which regression algorithm to use is very critical in the drug response 
estimation. We want to obtain few pathways out of 133 pathways that discriminates the responding and 
non-responding groups. A common pitfall results from overfitting the curve to the data points – typically 
when the blue line tries to pass through every data point. Therefore, we decided to use Lasso regression.     
 
Figure 27 - Regression example in one dimension 
 
Lasso 
Lasso (Least Absolute Shrinkage and Selection Operator) penalizes the absolute size of the regression 
coefficient [50]. In addition, it is capable of reducing the variability and improving the accuracy of linear 
regression models. Lasso avoids overfitting by adding a regularization parameter to the equation above 
as following: 
min
𝑊
 ‖𝑃𝑊 − 𝑅‖2
2 +  𝛼 ‖𝑊‖1 
The added term is called L1 regularization. Another advantage of the L1 regularization is that it leads to 
penalizing (or equivalently constraining the sum of the absolute values of the estimates) values which 
causes some of the parameter estimates to turn out exactly zero. Larger the penalty applied, further the 
estimates get shrunk towards absolute zero. This results to variable selection out of given n variables. So, 
running the Lasso regression with different values of 𝛼 will lead to many pathways to be cancelled out 
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(given a coefficient of zero). Running Lasso on our matrix using different values of 𝛼  results in the 
following coefficients (Table 6) 
Table 6 – Coefficient values at different values of 𝜶 
𝜶 rss intercept coef_x_1 coef_x_2 coef_x_3 … coef_x_133 
Cancelled 
Pathways 
𝟏𝟎−𝟏𝟓 0.96 0.22 0.6 -0.37 0.0016 … 10−8 6 
𝟏𝟎−𝟏𝟎 0.96 0.22 0.6 -0.37 0.0016 … 10−8 6 
𝟏𝟎−𝟖 0.96 0.22 0.6 -0.37 0.0016 … 10−8 6 
𝟏𝟎−𝟓 0.96 0.5 0.2 -0.13 0 … 10−6 103 
𝟏𝟎−𝟒 1 0.9 0.1 -0.048 0 … 10−6 115 
𝟏𝟎−𝟑 1.7 1.3 0.01 0 0 … 10−3 116 
𝟏𝟎−𝟐 3.6 1.8 -0.55 0 0 … 10−3 120 
1 37 0.038 0 0 0 … 0 133 
5 37 0.038 0 0 0 … 0 133 
10 37 0.038 0 0 0 … 0 133 
 
We have tried the Lasso regression with different weights of 𝛼 to decide an appropriate value that can be 
used. As we can see in Table 6, the largest values of 𝛼 made all the coefficients equal to 0. The smallest 
values of 𝛼 only cancelled 6 pathways leaving us with 127 pathways to investigate, which is a large 
number. We have chosen the values of 𝛼 in the middle rows (highlighted) as they cancel a large number 
of pathways, but leave us with the most important pathways that have an effect on the drug response.  
We can deduce that positive coefficients mean that the corresponding pathways promote the drug 
response since they are trying to predict a value of ?̂? close to 𝑅 = 1. Similarly, negative coefficients can 
be thought of promoting resistance as they are trying to predict a value of ?̂? close to 𝑅 = 0. Table 7 
shows the pathways that are not cancelled along with their corresponding coefficients for each value of 
the chosen alphas. We have highlighted the pathways that drive drug response with blue and pathways 
that drive resistance with red. Pathways that are not highlighted are opted out from our further analysis 
since they are either not related to gene regulations or their coefficients are mostly zero for 𝛼 values. 
Now, we can manually investigate the pathways that promote resistance and filter out those that are not 
related to cancer. For this step, we have looked at each pathway description on the KEGG database. 
Four of these pathways have biological meaningful fictions regarding tumor growth and are most likely 
related to the drug resistance in our study: 
1. KEGG_CELL_CYCLE 
Brief description: Mitotic cell cycle progression is accomplished through a reproducible sequence of 
events, DNA replication (S phase) and mitosis (M phase) separated temporally by gaps known as G1 
and G2 phases. 
Link: http://software.broadinstitute.org/gsea/msigdb/cards/KEGG_CELL_CYCLE.html  
2. KEGG_HOMOLOGOUS_RECOMBINATION 
Brief description: Homologous recombination (HR) is essential for the accurate repair of DNA double-
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strand breaks (DSBs), potentially lethal lesions. 
Link: http://software.broadinstitute.org/gsea/msigdb/cards/KEGG_HOMOLOGOUS_RECOMBINATION.html  
3. KEGG_INOSITOL_PHOSPHATE_METABOLISM 
Brief description: Inositol phosphate metabolism. 
Link: 
http://software.broadinstitute.org/gsea/msigdb/cards/KEGG_INOSITOL_PHOSPHATE_METABOLISM.html  
4. KEGG_TGF_BETA_SIGNALING_PATHWAY 
Brief description: A wide spectrum of cellular functions such as proliferation, apoptosis, differentiation 
and migration are regulated by TGF-beta family members. 
Link: http://software.broadinstitute.org/gsea/msigdb/cards/KEGG_TGF_BETA_SIGNALING_PATHWAY.html  
Table 7 - Pathways from Lasso regression 
Pathway ID (KEGG) 
coef 
at 𝜶 =
𝟏𝟎−𝟓 
coef 
at 𝜶 =
𝟏𝟎−𝟒 
coef 
at 𝜶 =
𝟏𝟎−𝟑 
coef 
at 𝜶 =
𝟏𝟎−𝟐 
KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION 0.0425 0.039 0.014 0.0519 
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION -0.019 0 0 0 
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION -0.001 0 0 0 
KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION -0.020 0 0 0 
KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION 0.043 0 0 0 
KEGG_N_GLYCAN_BIOSYNTHESIS -0.027 -0.02 -0.01 -0.02 
KEGG_PPAR_SIGNALING_PATHWAY 0.069 0.0863 0.090 0.0480 
KEGG_FOCAL_ADHESION 0.066 0.105 0.153 0.036 
KEGG_INSULIN_SIGNALING_PATHWAY 0.008 0 0 0 
KEGG_OXIDATIVE_PHOSPHORYLATION -0.051 -0.069 -0.088 0 
KEGG_RNA_DEGRADATION 0.008 0 0.0005 0.005 
KEGG_INOSITOL_PHOSPHATE_METABOLISM -0.001 -0.008 -0.018 -0.017 
KEGG_LONG_TERM_POTENTIATION 0.071 0.081 0.085 0.061 
KEGG_PRIMARY_BILE_ACID_BIOSYNTHESIS 0 0.0003 0 0 
KEGG_TGF_BETA_SIGNALING_PATHWAY -0.078 -0.043 -0.015 0 
KEGG_ADHERENS_JUNCTION 0.072 0.0625 0.0372 0 
KEGG_CYSTEINE_AND_METHIONINE_METABOLISM 0.0015 0 0 0 
KEGG_OOCYTE_MEIOSIS 0.0037 0 0 0 
KEGG_TYROSINE_METABOLISM 0.0054 0 0 0 
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY -0.040 -0.048 -0.019 0 
KEGG_GLIOMA 0.0001 0 0 0 
KEGG_CELL_CYCLE -0.035 -0.038 -0.017 -0.022 
KEGG_RENAL_CELL_CARCINOMA 0.0320 0 0 0 
KEGG_VIBRIO_CHOLERAE_INFECTION 0 0.0185 0.0052 0.0051 
KEGG_AMYOTROPHIC_LATERAL_SCLEROSIS_ALS -0.022 0 0 0 
KEGG_SPLICEOSOME -0.054 -0.062 -0.065 -0.021 
KEGG_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM -0.002 0 0 0 
KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR -0.052 -0.058 -0.068 -0.031 
 37 
KEGG_PURINE_METABOLISM 0.0427 0.0624 0 0.0688 
KEGG_HOMOLOGOUS_RECOMBINATION 0 -0.004 -0.023 0 
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS 0.0128 0.0060 0.0033 0.0032 
KEGG_OLFACTORY_TRANSDUCTION 0.0009 0 0 0 
KEGG_VEGF_SIGNALING_PATHWAY -0.004 0 0 0 
 
Backtracking 
Now that we have narrowed down our research to four pathways, the next step has been to look back at 
the aberrant genes for each non-responding patient, which engage in these four pathways. We compute 
the overlap matrix as following: 
𝑂𝑣𝑒𝑟𝑙𝑎𝑝 =  
[
 
 
 
 
 
 
CELL CYC __
𝑝1 … 𝑝𝑛
…
HOMOLOG __
INOSITOL __
TGF BETA __
…
…
… ]
 
 
 
 
 
Each cell of the overlap matrix represents a vector of aberrant genes for patient 𝑝𝑖 that are a subset of 
the corresponding pathway. Then, we have looked at each row of this matrix and identify the most 
frequent genes that appear in all non-responding patients, but not appearing in the responding group. 
Then, we have ordered genes in a descending order from most frequent to least frequent. Results are 
presented in Table 8. 
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Table 8 - Genes driving drug resistance 
Gene Pathway 
Significance to 
drug resistance 
Biological Validation 
PIK3CB 
Inositol 
phosphate 
metabolism 
High 
PIK3CB (Phosphatidylinositol-4,5-Bisphosphate 3-
Kinase Catalytic Subunit Beta) is a Protein Coding 
gene. PI 3-Kinases (phosphoinositide 3-kinases, PI 
3-Ks) are a family of lipid kinases capable of 
phosphorylating the 3'OH of the inositol ring of 
phosphoinositides. They are responsible for 
coordinating a diverse range of cell functions 
including proliferation and survival. 
PIK3C2B 
Inositol 
phosphate 
metabolism 
High 
PIK3C2B (Phosphatidylinositol-4-Phosphate 3-
Kinase Catalytic Subunit Type 2 Beta) is a Protein 
Coding gene. It belongs to the same family as 
PIK3CB. 
RAD52 
Homologous 
recombination 
High 
RAD52 (RAD52 Homolog, DNA Repair Protein) is a 
Protein Coding gene. Involved in double-stranded 
break repair. It plays a central role in genetic 
recombination and DNA repair by promoting the 
annealing of complementary single-stranded DNA 
and by stimulation of the RAD51 recombinase. 
RPA4 
Homologous 
recombination 
High 
RPA4 (Replication Protein A4) is a Protein Coding 
gene. As part of the alternative replication protein A 
complex, aRPA, binds single-stranded DNA and 
probably plays a role in DNA repair. 
PITX2 
TGF-beta 
signaling 
pathway 
High 
PITX2 (Paired Like Homeodomain 2) is a Protein 
Coding gene. It controls cell proliferation in a tissue-
specific manner and is involved in morphogenesis. 
MCM3 Cell cycle High 
MCM3 (Minichromosome Maintenance Complex 
Component 3) is a Protein Coding gene. It acts as 
component of the MCM2-7 complex (MCM complex) 
which is the putative replicative helicase essential for 
once per cell cycle DNA replication initiation and 
elongation in eukaryotic cells. 
MRE11A 
Homologous 
recombination 
Medium 
MRE11A (MRE11 Homolog A, Double Strand Break 
Repair Nuclease) is a Protein Coding gene. It is a 
component of the MRN complex, which plays a 
central role in double-strand break (DSB) repair, DNA 
recombination, maintenance of telomere integrity and 
meiosis. 
POLD3 
Homologous 
recombination 
Medium 
POLD3 (DNA Polymerase Delta 3, Accessory 
Subunit) is a Protein Coding gene. It is required for 
optimal DNA polymerase delta activity. 
EP300 Cell cycle Medium 
EP300 (E1A Binding Protein P300) is a Protein 
Coding gene. Bromodomains (BRDs) are epigenetic 
reader domains that selectively recognize acetylated 
lysine residues on the tails of histone proteins, and 
are the only known protein modules that can target 
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acetylated lysine residues. 
INPPL1 
Inositol 
phosphate 
metabolism 
Medium 
INPPL1 (Inositol Polyphosphate Phosphatase Like 1) 
is a Protein Coding gene. It plays a central role in 
regulation of PI3K-dependent insulin signaling, 
although the precise molecular mechanisms and 
signaling pathways remain unclear. 
EP300 
TGF-beta 
signaling 
pathway 
Medium 
EP300 (E1A Binding Protein P300) is a Protein 
Coding gene. Bromodomains (BRDs) are epigenetic 
reader domains that selectively recognize acetylated 
lysine residues on the tails of histone proteins, and 
are the only known protein modules that can target 
acetylated lysine residues. 
RAD54L 
Homologous 
recombination 
Low  
MUS81 Low  
BLM Low  
ORC6 
Cell cycle 
Low  
STAG1 Low  
ATR Low  
CCND2 Low  
TFDP2 Low  
YWHAB Low  
CHEK1 Low  
ORC4 Low  
HDAC1 Low  
WEE2 Low  
CDKN2C Low  
CCNE1 Low  
PLCZ1 
Inositol 
phosphate 
metabolism 
Low  
PLCB1 Low  
INPP5E Low  
INPP5B Low  
INPP4A Low  
ITPK1 Low  
PLCG1 Low  
ID1 
TGF-beta 
signaling 
pathway 
Low  
PPP2R1B Low  
BMP2 Low  
BMP7 Low  
ACVR1 Low  
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Chapter 5: Discussion 
Cancer is a complicated disease and curing it requires enormous amount of efforts in many different 
directions. Some researchers have been focusing on understanding the disease development. Others 
have been studying possible treatments. In all directions, the ground truth is that the study of cancer 
genomics speeds up our progress toward curing the disease. Although every cancer patient has his/her 
own case of genomic aberrations that caused the disease, a comprehensive analysis of a large number 
of patients helps us find common aberrations that will serve as a key point-of-focus for further studies. 
Given the genomic data of phase-1 clinical trial on 35 patients, our research question was to find 
candidate biomarkers for the drug resistance using limited number of samples (which is the case for all 
clinical trial studies). We run an unbiased, data driven and personalized approach to shed light on driver 
pathways and genes for drug resistance. Our story of following the data science approach can be 
described as looking for a needle in a haystack. Over 5 terabytes of data have been analyzed to extract 
a summary of the candidate genes that drive drug resistance when aberrant. Interestingly, the final 
results – the 4 pathways and the genes with higher score in Table 8 – potentially showed a biological 
meaning associated with drug response. We believe that aberrations in these genes can significantly 
contribute to the drug resistance shown in the given dataset. Of course, the wet lab validation of the 
candidate biomarker is required. Our goal is to generate a short list of candidate biomarker to facilitate 
the process of biomarker discovery. 
During the lifetime of this study, we have faced a number of challenges that we had to deal with.  
1. Big data nature: as we have seen in chapter 3, genomic data is very large in size. This nature 
implies a difficulty in designing and running automated pipelines. Computations takes a long time 
and if for some reason running computations failed, we do not want to re-run the whole pipeline 
from the beginning; that would be inefficient and time consuming. We have coded scripts that 
automate the pipeline execution. 
2. Small number of samples: even though the size of the data is very large, they only represent a 
small number of samples. That’s why conventional statistical analysis and machine learning 
techniques do not work. Using prior knowledge (pathways) and personalized approach (per 
patient analysis), we were able to tackle the problem from a different angle. 
3. Data heterogeneity: the genomic features under study come from different resources and 
represent different meanings. In addition, they come in different file formats. Thus, we had to pre-
process the data to come up with an abstract way of presenting them – using matrices. 
4. Integrative analysis: due to the small number of samples and the fact that there is many missing 
information (represented as 𝜃 parameters), running our analysis on the micro-level of aberrant 
genes failed to classify the two groups. Consequently, we had to zoom out into a bigger view on 
the genomic features – pathways. Running regression on pathways was a successful trial in our 
case. 
For the above challenges, conventional methods do not perform well. Linear and non-linear 
dimensionality reduction methods cannot find a smaller set of genes that do the classification. Applying 
regression on aberrant genes fails since the number of genes is very large relative to the number of 
samples. Perhaps the biggest limitation we have is the small number of samples that prevent us from 
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generalizing conclusions. The main advantage of the proposed approach is that analysis was done per 
patient. This means that we can gain a higher level of confidence with the results. Moreover, the data-
driven and unbiased approach that does not make any assumption about the distributions of the data 
offer a strong aspect on solving such problems. On the flip side, this approach might not be the best one 
to follow if the number of samples is very large, since we will end up with a large number of pathways as 
features. 
This study has generated tons of data that can be further investigated by clinicians and specialists. We 
can summarize our contribution in this study in the following points: 
1. Developing the data analysis pipelines that anatomize raw sequencing data into meaningful 
information. 
2. Researching and implementing different data analysis techniques – borrowed from the data 
science domain – on the processed data. 
3. Developing a method by integrating prior knowledge (from pathways) with genomics data of 
limited number of sample to identify biologically meaningful candidate biomarkers. Finding clues 
to the main research question: “can we identify candidate genomic biomarkers that drive drug 
resistance?”, and suggesting answers. 
Future Work 
With advances in sequencing technologies and the availability of an increasing amount of high 
throughput genomics data, the use of advanced computational methods to analyze, integrate, and mine 
the huge amount of genomics data is an absolute necessity. We see this study as one building block 
toward a broader integrative analysis of genomics data that will also include microRNA, ChIP-Seq and 
Methylation data. Our future research steps are: 
1. Cross-validation of the results using other software packages in the pipeline analysis. 
2. Investigate the prevalence of the identified candidate biomarkers using TCGA data. 
3. Integrate the pathway analysis part into the pipelines. 
4. Develop a fully-automated pipeline that takes raw sequencing data and perform all the analysis in 
the steps followed in this study. 
5. Include clinical data such as age, race and tumor stage into our feature set. 
To conclude, our research focus would be on optimizing the computational pipelines and enhancing the 
unbiased and data-driven analysis approach. 
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List of Abbreviations 
CNV – Copy Number Variation 
DE – Differential Expression 
DNA – Deoxyribonucleic Acid 
ER – Estrogen Receptors 
FC – Fold Change 
FDR – False Discovery Rate 
FPKM – Fragments Per Kilobase of transcript per Million mapped reads. 
GRN – Gene Regulatory Network 
Lasso – Least Absolute Shrinkage and Selection Operator 
PCA – Principle Component Analysis 
PR – Progesterone Receptor  
RNA – Ribonucleic Acid 
RNA-Seq – RNA Sequencing 
RPK – Reads Per Kilobase 
SAM – Sequence Alignment/Mapping 
SGOL – Segment Gain Or Loss 
SNP – Single Nucleotide Polymorphism 
TCGA – The Cancer Genome Atlas 
TNBC – Triple Negative Breast Cancer 
TPM – Transcripts Per Million 
VCF – Varian Calling Format 
WES – Whole Exome Sequencing 
 
References 
1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–24.  
2. Worldwide cancer statistics [Internet]. 2012. Available from: http://www.cancerresearchuk.org/health-
professional/cancer-statistics/worldwide-cancer 
3. Department of Defense Breast Cancer Research Program. The Breast Cancer Landscape [Internet]. 
Department of Defense Breast Cancer Research Program; 2016 Feb p. 11. Available from: 
http://cdmrp.army.mil/bcrp/ 
4. Azvolinsky A. Study Finds Ovarian and Basal-Like/Triple-Negative Breast Cancers Genetically Similar 
[Internet]. 2012. Available from: http://www.cancernetwork.com/triple-negative-breast-cancer/study-finds-
ovarian-and-basal-liketriple-negative-breast-cancers-genetically-similar 
5. JS R-F. Everything You’ve Always Wanted to Know About Triple-Negative Breast Cancers, Scientific 
Seminar [Internet]. London, UK; 2014. Available from: 
http://www.dako.com/us/index/knowledgecenter/kc_publications/white-papers-reviews-studies/breast-
cancer-diagnostics-symposia/triple-negative-breast-
cancers.htm?setCountry=true&purl=index/knowledgecenter/kc_publications/white-papers-reviews-
 43 
studies/breast-cancer-diagnostics-symposia/triple-negative-breast-
cancers.htm?undefined&submit=Accept%20country#.WBDQIJMrKYU 
6. Foulkes WD, Smith IE, Reis-Filho JS. Triple-Negative Breast Cancer. N. Engl. J. Med. 
2010;363:1938–48.  
7. Plaskocinska I, Shipman H, Drummond J, Thompson E, Buchanan V, Newcombe B, et al. New 
paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in 
Epithelial Ovarian Cancer (GTEOC) study. J. Med. Genet. 2016;53:655–61.  
8. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer Risks for BRCA1 and 
BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. JNCI J. Natl. Cancer Inst. 
2013;105:812–22.  
9. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, 
and prediction. The Lancet. 2011;378:1812–23.  
10. Guha N, Kwan ML, Quesenberry CP, Weltzien EK, Castillo AL, Caan BJ. Soy isoflavones and risk of 
cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. 
Breast Cancer Res. Treat. 2009;118:395–405.  
11. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat. 
Rev. Cancer. 2009;9:415–28.  
12. UConn High-Performance Computing Cluster [Internet]. Available from: 
http://bioinformatics.uconn.edu/ 
13. Lahti L, Schafer M, Klein H-U, Bicciato S, Dugas M. Cancer gene prioritization by integrative analysis 
of mRNA expression and DNA copy number data: a comparative review. Brief. Bioinform. 2013;14:27–35.  
14. Huang N, Shah PK, Li C. Lessons from a decade of integrating cancer copy number alterations with 
gene expression profiles. Brief. Bioinform. 2012;13:305–16.  
15. Kristensen VN, Lingjærde OC, Russnes HG, Vollan HKM, Frigessi A, Børresen-Dale A-L. Principles 
and methods of integrative genomic analyses in cancer. Nat. Rev. Cancer. 2014;14:299–313.  
16. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, et al. An Integrated Approach 
to Uncover Drivers of Cancer. Cell. 2010;143:1005–17.  
17. Nabavi S. Identifying candidate drivers of drug response in heterogeneous cancer by mining high 
throughput genomics data. BMC Genomics [Internet]. 2016 [cited 2016 Oct 26];17. Available from: 
http://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-016-2942-5 
18. Jennings EM, Morris JS, Carroll RJ, Manyam GC, Baladandayuthapani V. Bayesian methods for 
expression-based integration of various types of genomics data. EURASIP J. Bioinforma. Syst. Biol. 
2013;2013:13.  
19. Wang W, Baladandayuthapani V, Morris JS, Broom BM, Manyam G, Do K-A. iBAG: integrative 
Bayesian analysis of high-dimensional multiplatform genomics data. Bioinformatics. 2013;29:149–59.  
 44 
20. Görlich D, Kutay U. Transport Between the Cell Nucleus and the Cytoplasm. Annu. Rev. Cell Dev. 
Biol. 1999;15:607–60.  
21. Alberts B. Molecular biology of the cell. Sixth edition. New York, NY: Garland Science, Taylor and 
Francis Group; 2015.  
22. Sawicki MP, Samara G, Hurwitz M, Passaro E. Human Genome Project. Am. J. Surg. 1993;165:258–
64.  
23. Tucker T, Marra M, Friedman JM. Massively Parallel Sequencing: The Next Big Thing in Genetic 
Medicine. Am. J. Hum. Genet. 2009;85:142–54.  
24. Cock PJA, Fields CJ, Goto N, Heuer ML, Rice PM. The Sanger FASTQ file format for sequences with 
quality scores, and the Solexa/Illumina FASTQ variants. Nucleic Acids Res. 2010;38:1767–71.  
25. Hosny A. GitHub repository: Nabavi Lab/TNBC [Internet]. 2016. Available from: 
https://github.com/NabaviLab/TNBC_Project 
26. Andrews S. FastQC: A quality control tool for high throughput sequence data. 2010.  
27. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. 
Bioinformatics. 2009;25:1754–60.  
28. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The Human Genome 
Browser at UCSC. Genome Res. 2002;12:996–1006.  
29. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map 
format and SAMtools. Bioinformatics. 2009;25:2078–9.  
30. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome 
Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome 
Res. 2010;20:1297–303.  
31. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation 
discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 2011;43:491–8.  
32. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, del Angel G, Levy-Moonshine A, et al. From 
FastQ Data to High-Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline: The 
Genome Analysis Toolkit Best Practices Pipeline. In: Bateman A, Pearson WR, Stein LD, Stormo GD, 
Yates JR, editors. Curr. Protoc. Bioinforma. [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2013 
[cited 2016 Nov 9]. p. 11.10.1–11.10.33. Available from: 
http://doi.wiley.com/10.1002/0471250953.bi1110s43 
33. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: Somatic mutation 
and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22:568–76.  
34. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, et al. The variant call format 
and VCFtools. Bioinformatics. 2011;27:2156–8.  
 45 
35. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of 
array-based DNA copy number data. Biostatistics. 2004;5:557–72.  
36. Hsu F, Kent WJ, Clawson H, Kuhn RM, Diekhans M, Haussler D. The UCSC Known Genes. 
Bioinformatics. 2006;22:1036–46.  
37. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-
throughput sequencing data. Nucleic Acids Res. 2010;38:e164–e164.  
38. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 
2009;10:57–63.  
39. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal 
RNA-seq aligner. Bioinformatics. 2013;29:15–21.  
40. Haas BJ, Zody MC. Advancing RNA-Seq analysis. Nat. Biotechnol. 2010;28:421–3.  
41. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a 
reference genome. BMC Bioinformatics. 2011;12:323.  
42. Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, et al. Ensembl 2016. Nucleic 
Acids Res. 2016;44:D710–6.  
43. Nicorici D, Satalan M, Edgren H, Kangaspeska S, Murumagi A, Kallioniemi O, et al. FusionCatcher - 
a tool for finding somatic fusion genes in paired-end RNA-sequencing data [Internet]. 2014 Nov. Report 
No.: 011650. Available from: http://biorxiv.org/lookup/doi/10.1101/011650 
44. Zhang J, Feng B. cghMCR: Find chromosome regions showing common gains/losses. R package 
version 1.32.0 [Internet]. 2016. Available from: 
http://mirror.ufs.ac.za/bioconductor/packages/3.4/bioc/html/cghMCR.html 
45. Leng N, Dawson JA, Thomson JA, Ruotti V, Rissman AI, Smits BMG, et al. EBSeq: an empirical 
Bayes hierarchical model for inference in RNA-seq experiments. Bioinformatics. 2013;29:1035–43.  
46. Principal Component Analysis [Internet]. New York: Springer-Verlag; 2002 [cited 2016 Oct 26]. 
Available from: http://link.springer.com/10.1007/b98835 
47. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set 
enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. 
Proc. Natl. Acad. Sci. 2005;102:15545–50.  
48. Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28:27–30.  
49. Chamberlain G. Multivariate regression models for panel data. J. Econom. 1982;18:5–46.  
50. Tibshirani R. Regression Shrinkage and Selection via the Lasso. J. R. Stat. Soc. Ser. B Methodol. 
[Internet]. 1996;58. Available from: http://www.jstor.org/stable/2346178?seq=1#page_scan_tab_contents 
 
